Impact of a clinical pharmacy consult service on guideline adherence and management of gabapentin for neuropathic pain

Journal of Managed Care Pharmacy

Volumn 12, Issue 1, 2006, Pages 61-69

  Winterbottom, Lisa M ^a,b,c   Fong, Anna M ^c   Benkstein, Kristen L ^c   Liang, Bingbing ^c   Snodgrass, Leann S ^c   Parks Huitron, Heather ^c  

^a Nephrology Section   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Clinical pharmacy; Formulary management; Gabapentin; Neuropathic pain

Indexed keywords

AMITRIPTYLINE; CAPSAICIN; DESIPRAMINE; DOXEPIN; GABAPENTIN; IBUPROFEN; IMIPRAMINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; TRICYCLIC ANTIDEPRESSANT AGENT; 4 AMINOBUTYRIC ACID; AMINE; ANALGESIC AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE;

ARTICLE; AUTOMATION; CLINICAL PHARMACY; CONSULTATION; CONTROLLED STUDY; DRUG USE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; NEUROPATHIC PAIN; PAIN ASSESSMENT; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRESCRIPTION; TREATMENT INDICATION; HOSPITAL PHARMACY; ORGANIZATION AND MANAGEMENT; PAIN; PATIENT REFERRAL; PUBLICATION; RETROSPECTIVE STUDY; UNITED STATES;

AMINES; ANALGESICS; CYCLOHEXANECARBOXYLIC ACIDS; FORMULARIES; GAMMA-AMINOBUTYRIC ACID; GUIDELINE ADHERENCE; GUIDELINES; HUMANS; OREGON; PAIN; PHARMACY SERVICE, HOSPITAL; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES;

EID: 33646547291     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2006.12.1.61     Document Type: Article

References (42)

1. U.S. Food and Drug Administration, NDA 20-235/S-029; NDA 20-882/S-015; NDA 21-129/S-016, Neurontin (gabapentin) capsules, Neurontin (gabapentin) tablets, Neurontin (gabapentin) oral solution. FDA-approved labeling text dated February 2005.
2. Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2005;20;(3):CD001133.
3. Sindrup SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain. 1999;83(3):389-400.
4. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995;311:1047-52.
5. Top 200 brand-name drugs by unit. Drug Top. Available at: http://www.drugtopics.com/drugtopics/article/articleDetail.jsp?id = 104555. Accessed December 15, 2004.
6. Neurontin (gabapentin). The illegal corporate creation of Neurontin, the illegal creation of a blockbuster drug. eLetter on Drugs for Severe Psychiatric Illnesses. Public Citizen - The Health Research Group. Available at: http://www.citizen.org/hrg/drugs/articles.cfm?ID=6163.
7. Peterson M. Doctor explains why he blew the whistle. New York Times, March 12, 2003:C1.
8. U.S. Food and Drug Administration. Drug maker to pay $430 million in fines, civil damages. FDA Consum. July-August 2004. Available at: http://www.fda.gov/fdac/features/2004/404_wl.html. Accessed June 5, 2005.
9. Hamer AM, Haxby DG, McFarland BH, Ketchum K. Gabapentin use in a managed Medicaid population. J Manag Care Pharm. 2002;8(4):266-71.
10. Barbuto, JP. Gabapentin and indications of appropriate use (editorial). J Manag Care Pharm. 2002:8(4):293-94.
11. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6):559-68.
12. Davis S. Gabapentin may be appropriate for off-label uses (editorial). J Manag Care Pharm. 2003;9(6):569-70.
13. Collins SL, Moore RA, McQuay HJ, Wiffen P. Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review. J Pain Symptom Manage. 2000;20:449-58.
14. Rice AS, Maton S. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo-controlled study. Pain. 2001;94:215-24.
15. Rowbotham M, Harden N, Stacy B. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.
16. Alper BS, Lewis PR. Treatment of postherpetic neuralgia: a systematic review of the literature. J Fam Pract. 2002;51:121-28.
17. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization; 1990.
18. Allegrante JP. The role of adjunctive therapy in the management of non-malignant pain. Am J Med. 1996;101:33S.
19. Capsaicin drug information. MICROMEDEX(R) Health Care Series. Vol. 122. Expired December 2004.
20. McCormack K. Nonsteroidal anti-inflammatory drugs and spinal nociceptive processing. Pain. 1994;59:9.
21. Neurontin [2002 package insert; information no longer available.] Initial recommended doses were not as high as those on current package insert. Available at: http://www.pfizer.com/pfizer/download/uspi_neurontin.pdf. Accessed December 23, 2005.
22. National Guideline Clearinghouse. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations, May 4, 2004. Available at: http://www.guideline.gov/summary/summary.aspx?doc_id = 4671&nbr = 003405&string = %22Advances+in+neuropathic+pain%3a+diagnosis%2c+mechanisms%2c+and+ treatment+recommendations.%22. Accessed November 25, 2005.
23. Kaiser Permanente Health Matters. "Neuropathic pain" patient information; 2002. The Permanente Medical Group, Inc. Regional Health Education; 915800037 (revised April 2005) RL 9.5. Available at: http://www.permanente.net/ kaiser/pdf/14211.pdf. Accessed December 23, 2005.
24. Dworkin RH, Backonja M, Rowbotham MC, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11):1524-34.
25. Backonja M, Beydoun A, Edwards KR, et al., for the Gabapentin Diabetic Neuropathy Study Group. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280:1831-36.
26. Rowbotham M, Harden N, Stacey B, Bernstein P, Magnus-Miller L, for the Gabapentin Postherpetic Neuralgia Study Group. Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA. 1998;280:1837-42.
27. Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo-controlled, double-blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66:251-52.
28. Rice AS, Maton S, Postherpetic Neuralgia Study Group. Gabapentin in postherpetic neuralgia: a randomized, double blind, placebo controlled study. Pain. 2001;94:215-24.
29. Serpell MG, Neuropathic Pain Study Group. Gabapentin in neuropathic pain syndromes: a randomized, double blind, placebo-controlled trial. Pain. 2002;99:557-66.
30. Bone M, Critchley P, Buggy DJ. Gabapentin in postamputation phantom limb pain: a randomized, double-blind, placebo-controlled, cross-over study. Reg Anesth Pain Med. 2002;27:481-86.
31. Pandey CK, Bose N, Garg G, et al. Gabapentin for the treatment of pain in Guillain-Barre syndrome: a double-blind, placebo-controlled, crossover study. Anesth Analg. 2002;95:1719-23.
32. Tai Q, Kirshblum S, Chen B, Millis S, Johnston M, DeLisa JA. Gabapentin in the treatment of neuropathic pain after spinal cord injury: a prospective, randomized, double-blind, crossover trial. J Spinal Cord Med. 2002;25:100-05.
33. Gabapentin [drug information]. An official reprint from UpToDate. Available at: http://www.utdol.com/application/topic.asp?file = drug_a_k/113590&type = A&selectedTitle = 1~48. Accessed November 25, 2005.
34. Gabapentin price information. Available at: http://www.drugstore.com. Accessed December 23, 2005.
35. Sasane RM, Shepherd MD, Lawson KA. An assessment of the effectiveness of a nonsteroidal anti-inflammatory drugs algorithm in an integrated health care system. J Manag Care Pharm. 2001;7(20):149-55.
36. Bull SA, Conell C, Campen DH. Relationship of clinical factors to the use of COX-2 selective NSAIDs within an arthritis population in a large HMO. J Manag Care Pharm. 2002;8(4):252-58.
37. Curtiss FR. Actual prescribing versus guidelines [editorial]. J Manag Care Pharm. 2002;8(4):297-99.
38. Curtiss FR. Who needs another clinical practice guideline? [editorial]. J Manag Care Pharm. 2004;10(5):456-58.
39. Yokoyama KK, Doan QD, Godley PJ, et al. Effect of physician profiles and academic detailing on cost and utilization of selective serotonin reuptake inhibitors. J Manag Care Pharm. 2002;8(1):23-31.
40. McMullin ST, Lonergan TR, Rynearson CS. Twelve-month drug cost savings related to the use of an electronic prescribing system with integrated decision support in primary care. J Manag Care Pharm. 2005;11(4):322-32.
41. Burk M, Furmaga E, Dong D, Cunningham F. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the Veterans Affairs health system. J Manag Care Pharm. 2004;10(5):423-32.
42. Peabody JW, Luck J, Glassman P, Dresselhaus TR, Lee M. Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality. JAMA. 2000;283:1715-22.